UPDATE: Wedbush Downgrades Ironwood Pharmaceuticals; Lowers PT

According to a research report published earlier today, Wedbush has downgraded Ironwood Pharmaceuticals IRWD from Outperform to Underperform, and has lowered its PT from $20 to $8. In the report, Wedbush explained, “Our 12 month price target represents the net-present value (25% discount rate) of IRWD's change in cash from 2012 to 2015 and 15x 2016 fully-taxed income – a year we are expecting $1 billion in US sales) using our projected 150 million fully-diluted share count (125 million current and 25 million additional shares). We do not believe owning IRWD's shares going into the FDA approval is going to be a good trade as based upon our outlook, we expect significant selling pressure in the stock with or without a positive FDA outcome.” Ironwood Pharmaceuticals is currently trading at $13.06.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorDowngradesPrice TargetAnalyst RatingsWedbush
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!